IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently, there are seven named IGF-BPs that form high-affinity complexes with both IGF-I and IGF-II. IGF-BP1 is a 25.4 kDa, cysteine-rich, secreted protein expressed in the liver, deciduas, kidneys, and in amniotic fluid, where it is the most abundant IGF-BP. Levels of IGF-BP1 in serum are lowest after food consumption. IGF-BP1 binds to both IGF-I and IGF-II with equal affinity. Phosphorylated IGF-BP1 hinders IGF actions, whereas nonphosphorylated IGF-BP1 is stimulatory. Recombinant Human IGF-BP1 is a 25.4 kDa protein consisting of 235 amino acid residues (Isoform A).
Insulin-like Growth Factor-Binding Protein 1, IBP-1, Placenta Protein 12 (PP12)
MAPWQCAPCS AEKLALCPPV SASCSEVTRS AGCGCCPMCA LPLGAACGVA TARCARGLSC RALPGEQQPL HALTRGQGAC VQESDASAPH AAEAGSPESP ESTEITEEEL LDNFHLMAPS EEDHSILWDA ISTYDGSKAL HVTNIKKWKE PCRIELYRVV ESLAKAQETS GEEISKFYLP NCNKNGFYHS RQCETSMDGE AGLCWCVYPW NGKRIPGSPE IRGDPNCQIY FNVQN
≥ 98% by SDS-PAGE gel and HPLC analyses.
The ED50 was determined by its ability to inhibit IGF-I induced proliferation of MCF-7 is ≤ 0.5 μg/ml in the presence of 6 ng/ml of human IGF-I.
Calculated Molecular Weight:
Endotoxin level is < 0.1 ng/ug of protein (< 1 EU/ug)
Not for human use.